16-18 March, 2021

Digital Event | www.tpd-europe.com

8.30 - 17.30 | GMT

REGISTER BY FRIDAY 20 NOVEMBER TO SAVE UP TO £200

TPD Europe

Targeted Protein Degradation

Successfully Discover Novel E3 Ligases & Optimise Drug-Like Properties to Harness the Full Therapeutic Opportunity of Orally Bioavailable Protein Degraders in Oncology & Beyond

Expert Speakers Include:

Alessio Ciulli
Professor of Chemical & Structural Biology
University of Dundee

Brenda Schulman
Director of Molecular Machines and Signaling & Acting Executive Director
Max Planck Institute of Biochemistry

Georg Winter
Principal Investigator
CeMM Research Centre for Molecular Medicine

John Harling
Senior Scientific Director of Medicinal Chemistry
GSK

Ian Churcher
Chief Scientific Officer
Amphista Therapeutics

Laura Luh
Research Scientist
Bayer

Proud to Partner with:

Promega HITGEN SCHRÖDINGER Selvita proteome sciences TEMPER RE•FEYN

+44 (0)20 3141 8700 info@hansonwade.com

hansonwade

Targeted Protein Degradation Europe Summit

The exciting progression of PROTAC-based therapies and other degrader modalities continues to redefine the therapeutic landscape among the biopharmaceutical industry. As the quest to 'drug the undruggable' with targeted protein degradation heats up, challenges still remain to advance orally bioavailable candidates towards the clinic.

Coming to you in a digital capacity this year, the **Targeted Protein Degradation Europe Summit** provides you with a platform of learning, discovery, and networking opportunities to hear the latest developments and advancements from the leaders of the protein degradation field, to maximise the therapeutic window of your TPD strategies.

Bringing together the leading biopharmaceutical and academic organisations from the European scene in an intimate digital environment, TPD Europe focuses on **successfully discovering novel E3 ligases and optimising drug-like properties to harness the full therapeutic opportunity of orally bioavailable protein degraders in oncology and beyond.**

With the goal of accelerating the translation of selective, bioavailable and effective protein degraders towards clinical trials, join **100+ pioneers, leaders and enthusiasts** to capitalise on this emerging therapeutic class and make targeted protein degradation a blockbuster approach that improves patient outcomes.

Hear what our 2021 speakers have to say

"Developments in protein engineering coupled with delivery methods will be a major step in therapy development. This meeting will provide an important forum for discussing these issues with reference to targeted protein degradation"

Terry Rabbitts, Professor of Molecular Immunology, **The Institute of Cancer Research**

"Participation in this meeting will allow me to connect with leaders in academia and industry, exchange thoughts, explore possibilities for collaborations and to further extend the research of my academic lab to impact definitive drug development efforts"

Georg Winter, Principal Investigator, **CeMM Research Centre for Molecular Medicine**

Why Attend Targeted Protein Degradation Europe?

Discover the full potential of protein degrader approaches to open up therapeutic opportunity with insights from **Alessio Ciulli, Brenda Schulman & Georg Winter**

Diversify TPD strategies by uncovering novel E3 ligases with insights from **AstraZeneca, Eli Lilly & PhoreMost**



Advance the horizon & impact of PROTAC-based targeted degradation with insights from **GSK, Bayer & Amphista Therapeutics**

Expand the horizon of targeted protein degradation beyond oncology and the UPS with insights from **Goethe University Frankfurt & The Institute of Cancer Research**

Harness alternative next-generation platforms for inducing protein degradation with insights from **Aelin Therapeutics & Mission Therapeutics**

Digital Events: An Interactive Online Experience

The **Targeted Protein Degradation Europe Summit** is committed to delivering the high-quality insights and industry connections that our customers expect, in a format that is accessible from the comfort of your home or office.

We have created this digital summit to satisfy the industry's need to share cutting-edge research, learn from your peers and engage in quality networking within a niche and highly selective audience to forge valuable collaborations.

To effectively facilitate this need to learn and connect, our custom-built virtual event platform will combine best-in-class platforms to deliver a seamless event experience. Accessing the platform is simple, you'll be provided with a unique link in the run up to the event that will take you directly to the online event space where you'll follow a few simple steps to set up your delegate profile and get started.

Key Features & Functionalities:

Delegate Profile
Set up personalised profiles to easily identify the name, job title & company of other attendees

Stage Area
Most presentations will be delivered in the 'Stage' area, much like the main conference room onsite

Sessions Area
Smaller groups can get together in this breakout area for panel discussions and other interactive sessions

Demo Area
Visit the virtual exhibition area to explore the solutions our specialist partners have on offer

Chat Rooms
Conect with your peers and start conversations with individuals or all attendees in private and public chatrooms

Speed Networking
This virtual networking session will connect you with other attendees to establish new industry contacts

What You Can Expect from a Digital Event:

Live Q&As with Speakers
Ask your burning questions directly to our expert speakers in real-time, just as you would at a face-to-face conference

Audience Discussions
Join smaller, informal group chats or video calls designed to spark crucial conversations around key challenges for the industry

8+ Hours of Networking
Facilitated and informal networking breaks will allow you to connect 1-2-1 with other attendees and kick start critical discussions

Content Available Post-Event
On conclusion of the event, presentations will be made available to attendees where possible

+44 (0)20 3141 8700 info@hansonwade.com
www.tpd-europe.com
hansonwade

YOUR EXPERT SPEAKERS

Alexander Scheer
Chief Scientific Officer
Aelin Therapeutics

Ian Churcher
Chief Scientific Officer
Amphista Therapeutics

Guido Koch
Chief Executive Officer
Amphilix AG

Thomas Hayhow
Medicinal Chemist
AstraZeneca

Laura Luh
Research Scientist
Bayer

Georg Winter
Principal Investigator
CeMM Research Centre for Molecular Medicine

Bomie Han
Research Advisor
Eli Lilly

Gustavo Gutierrez
Principal Scientist
Galápagos NV

Ivan Dikic
Director of Institute of Biochemistry II
Goethe University Frankfurst

John Harling
Senior Scientific Director of Medicinal Chemistry
GSK

Jin Li
Chairman & Chief Executive Officer
HitGen

Brenda Schulman
Director of Molecular Machines and Signaling & Acting Executive Director
Max Planck Institute of Biochemistry

Paul Thompson
Chief Scientific Officer
Mission Therapeutics

Benedict Cross
Chief Technology Officer
PhoreMost

Danette Daniels
Group Leader of Functional Proteomics
Promega

Simon Bailey
Executive Vice President & Head of Drug Discovery
Plexium

Senior Representative
Refeyn

Tom Coulter
Director of Integrated Drug Discovery
Selvita

Agustina Rodriguez-Granillo
Principal Scientist II
Schrödinger

Terry Rabbitts
Professor of Molecular Immunology
The Institute of Cancer Research

David Rubinsztein
Professor of Molecular Neurogenetics & UK Dementia Research Institute
University of Cambridge

Gopal Sapkota
Principal Investigator
University of Dundee

Alessio Ciulli
Professor of Chemical & Structural Biology
University of Dundee

Alex Bullock
Associate Professor
University of Oxford

Elmar Wolf
Professor
University of Würzburg

> These meetings provide a valuable opportunity for focused interactions with both future potential collaborators and key experts in the field
>
> **Benedict Cross**, Chief Technology Officer, **PhoreMost**

WHY ARE OUR EXPERT SPEAKERS GETTING INVOLVED AT THE SUMMIT?

"I look forward to contributing to the TPD Europe as the flagship event bringing together the growing protein degradation community from across academia and the biopharma industry, within Europe and beyond"

Alessio Ciulli
Professor of Chemical & Structural Biology
University of Dundee

"This meeting offers a great opportunity to learn the latest in the rapidly advancing field of targeted protein degradation"

Brenda Schulman
Director of Molecular Machines and Signaling & Acting Executive Director
Max Planck Institute of Biochemistry

"There has been increasing interest and evidence for the therapeutic potential of modulating clearance pathways, along with exciting developments in targeting such processes. This is critical for my interest in neurodegenerative diseases and why I look forward to taking part at this meeting"

David Rubinsztein
Professor of Molecular Neurogenetics & UK Dementia Research Institute
University of Cambridge

"I look forward to exchanging ideas on current progress in the area of PROTAC and AUTAC technologies"

Ivan Dikic
Director of Institute of Biochemistry II
Goethe University Frankfurt

"I hope to get insights into successful ways to develop medicines based on targeted protein degradation"

Thomas Hayhow
Medicinal Chemist
AstraZeneca

PRE-CONFERENCE WORKSHOP DAY TUESDAY 16 MARCH

ALL TIMES SHOWN IN GMT

Workshop A — 8.30-10.30

Exploring the Autophagy-Lysosomal Pathway to Discover Novel Targeted Protein Degradation Strategies

The autophagy-lysosome pathway is becoming increasingly appreciated as playing a role in diverse diseases, including forms of neurodegeneration, infectious and inflammatory diseases and cancers. A growing literature suggests that strategies that may induce or inhibit autophagic flux can ameliorate such diseases, depending on their biology, based on cell and animal models. The next phases involve testing such strategies in human diseases. Such approaches may involve inhibiting the pathway at different points (for example in some cancers), or inducing bulk autophagy or pathways that enable some selective clearance of particular substrates. This workshop will consider target selection, target validation and strategies for therapeutic development.

Join this interactive workshop to discuss:

- How to identify suitable targets for autophagy modulation
- How to validate autophagy targets in specific diseases
- What approaches may be suitable for screening for autophagy modulators?
- What is the potential for designing strategies for selective autophagic clearance of toxic proteins?
- Is it important to consider the potential of other pathways, particularly chaperone-mediated autophagy?

Workshop Leader

David Rubinsztein
Professor of Molecular Neurogenetics & UK Dementia Research Institute
University of Cambridge

Workshop B — 11.00-13.00

Optimising the Medicinal Chemistry of New Modalities

Targeted protein degraders often position themselves at the edge of the property space previously considered as drug-like. The workshop will highlight opportunities and challenges associated with degrader modalities. The modular composition offer modular design and synthesis opportunities. Synthetic chemistry will play a key element in the understanding and optimisation of molecular properties required for improved oral bioavailability. Additional aspects covered in this workshop will include purification and scale-up strategies for complex molecules.

Join this interactive session to discuss:

- What tools can be applied for rapid exploration of new degrader targets (library design, automated synthesis)?
- Optimsation strategies for > rule-of-5 modalities
- Key parameters for improving oral bioavailability
- Missing elements in the medicinal chemistry / synthesis toolbox
- Translation of clinical candidates into development: challenges in purification and scale-up

Workshop Leader

Guido Koch
Chief Executive Officer
Amphilix AG

Workshop C

14.00-16.00

Mathematical Understanding of the Target Engagement or Ternary Complex Formation by the PROTAC or Molecular Glue Compounds & its Practical Implications

The target engagement for these molecules is a ternary complex (TC) formation among the target protein, the small molecule, and an E3 ubiquitin ligase protein. Unlike the traditional drugs where the target engagement can be described by a simple bimolecular equilibrium equation, there is currently no mathematical tools that can properly describe such complex multi-body interactions, which substantially increases the challenge in developing drugs of this mechanism. Due to the complex nature of the system, various conflicting empirical theories have been put forward in the past regarding optimal properties of these molecules. This workshop will provide multiple mathematical tools to address kinetics and equilibrium binding properties of the ternary complex formation, and practical implications will be discussed based on theoretical understanding of the system.

Join this interactive session to discuss:

- What are the practical implications of the "hook effect"? Why do I not observe the hook effect in my system? What does it tell us when that happens?
- What are the equivalent concepts in PROTAC world for Kd, EC50, Bmax, effective concentrations etc, and how to deduce them from biochemical measurements?
- Given the same cellular system, what determines efficacy of different PROTAC molecules? How do you choose one PROTAC over others from in vitro ternary complex assays? In other words, what parameters to use for SAR?
- Why do my PROTAC molecules fail to degrade the target protein? When different in vitro assays provide different pictures, how do I know which one to believe? How do I know when to quit or what aspect of the molecule needs to be improved?
- How to design PROTAC molecules to maximise efficacy and minimise toxicity? Is there such a thing as optimal affinity? Is extreme high affinity bad? What about covalent PROTAC?
- How to overcome low exposure, minimise hook effect or decreased efficacy at high dose, how to design tox studies given the complex nature of the system, and answering whether tox study design should be any different from traditional drugs?

Workshop Leader

Bomie Han
Research Advisor
Eli Lilly

> "Targeted protein degradation opens novel pharmaceutical strategies to target oncogenic proteins which are considered undruggable, so far. The field is exploding and the conference will allow me to learn about the latest developments."
>
> **Elmar Wolf,** Professor**, University of Würzburg**

CONFERENCE DAY ONE
WEDNESDAY 17 MARCH

ALL TIMES SHOWN IN GMT

8.30 **Online Registration & Networking Coffee**

8.55 **Chair's Opening Remarks**

KEYNOTE Session: Discovering the Full Potential of Protein Degrader Approaches to Open Up Therapeutic Opportunity

9.00 **Inducing Protein Degradation with Bifunctional Small Molecules**

Alessio Ciulli
Professor of Chemical & Structural Biology
University of Dundee

- Recent years have seen a resurgence of interest in designing bifunctional molecules that serve as bridging agents to bring proteins together
- Recruitment of target proteins to E3 ubiquitin ligases to induce protein degradation promises to significantly expand the range of tractable targets for chemical biology and therapeutic intervention
- Pioneering structural and biophysical studies of the ternary complexes formed by these molecules highlight that proximity-induced de novo formation of protein–protein interactions is a general feature of their molecular recognition

9.20 **Ubiquitylation by Cullin-RING E3 Ligases – How Targeted Protein Degradation is Possible**

Brenda Schulman
Director of Molecular Machines and Signaling & Acting Executive Director
Max Planck Institute of Biochemistry

- Overview of cullin-RING E3 structure
- Structural basis for cullin-RING E3 ubiquitylation
- Implications for targeted protein degradation

9.40 **Discovery of Molecular Glue Degraders via Phenotypic Chemical Screens**

Georg Winter
Principal Investigator
CeMM Research Center for Molecular Medicine

- Coupling genome-scale CRISPR screens with degrader treatment identifies a comprehensive network of cellular effectors required for efficient TPD
- Development of isogenic, hyponeddylated cell line models based on this effector network empowered differential chemical screening to identify novel and molecular glue degraders
- Multi-omics target identification led us to identify novel degraders of Cyclin K that operate via a unique mechanism that is independent of a dedicated substrate receptor

10.00 **Discussion/Q&A**

Alessio Ciulli
Professor of Chemical & Structural Biology
University of Dundee

Brenda Schulman
Director of Molecular Machines and Signaling & Acting Executive Director
Max Planck Institute of Biochemistry

Georg Winter
Principal Investigator
CeMM Research Center for Molecular Medicine

10.20 **Virtual Speed Networking**

Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

Utilising Next-Generation Approaches to Advance Novel Target Identification

Ivan Dikic
Director of the Institute of Biochemistry II
Goethe University Frankfurt

11.20 Targeting Protein Aggregates and Damaged Organelles via Autophagy and Lysosome Pathways

- Explore chemical approaches to induced selective autophagy in removing protein aggregates and non-functional organelles
- Better understand the cross talk between ubiquitin-proteasome and autophagy pathways
- Investigate the spectrum of E3 ligases to be used in PROTAC methods

Jin Li
Chairman & Chief Executive Officer
HitGen

11.40 Enabling DNA Encoded Libraries as a High Content Discovery Tool for Protein Degradation Molecules

- DNA encoded library (DEL) is an optimal discovery tool for protein degradation molecules because both techniques share the same key principles such as affinity binding selection and combination of structural blocks
- Our pilot study designed an E3 tri-conjugate DEL library with more than 390K compounds including BRD4 binder, 16 linkers and thalidomide. We captured novel dBET1 like compounds validated with BRD4 protein degradation using dual binder DEL selection method developed in house
- This DEL protein degradation system also generates other information such as binding affinity that helps predict protein degradation efficacy of compounds, and the system can be extended to other targets and E3 ligases of interest

12.10 Discussion/Q&A

Ivan Dikic
Director of the Institute of Biochemistry II
Goethe University Frankfurt

Jin Li
Chairman & Chief Executive Officer
HitGen

12.30 Lunch Break

Diversifying TPD Strategies by Uncovering Novel E3 Ligases

Thomas Hayhow
Medicinal Chemist
AstraZeneca

13.30 A Buchwald-Hartwig Protocol to Enable Rapid Linker Exploration of Cereblon E3-Ligase PROTACs

- CRBN binders have some of the best physicochemical properties to make PROTACs with that lie within the extended rule of five properties
- Existing methods to synthesise lenalidomide-like CRBN binders that vary the group to the isoindolinone require inserting chemical diversity at the first synthetic step
- We developed a robust Buchwald-Hartwig methodology to introduce a wide range of amines suitable for elaboration into full PROTACs

Gopal Sapkota
Principal Investigator
University of Dundee

13.50 Affinity-Directed PROtein Missile (AdPROM) System: Deploying Protein Missiles for Targeted Proteolysis of Endogenous Intracellular Proteins

- By using E3 ligases coupled to small polypeptide binders of POIs, the AdPROM system can efficiently target POI proteolysis in cells
- We have successfully used the AdPROM system to target the rapid degradation of many endogenous proteins, including SHP2, ASC and RAS isoforms and misfolded proteins in neurodegenerative disorders
- The efficiency and versatility of the AdPROM system allows to quickly identify degradation-capable E3 ligases in different cellular systems and rapidly informs whether targeted POI degradation confers suitable drugging strategy

Alex Bullock
Associate Professor
University of Oxford

14.10 Expanding the E3 Space for PROTAC Development

- E3 crystal structures and ligand screening show tractability for developing small molecule binders for a large range of E3s
- Developing binders for more E3s should increase the repertoire of substrates amenable to PROTAC-dependent degradation
- Tissue-selective E3 expression provides opportunity for tissue selective PROTAC

Danette Daniels
Group Leader of Functional Proteomics
Promega

14.30 Cellular Mechanistic Profiling of Degradation Compounds

- Several case studies to understand PROTAC mechanism of action in different systems
- Correlation of real-time kinetic degradation profiles to ternary complex formation and ubiquitination
- Cell-based assay strategies for rank ordering compound potency and efficacy

15.00 Discussion/Q&A


Thomas Hayhow
Medicinal Chemist
AstraZeneca


Gopal Sapkota
Principal Investigator
University of Dundee


Alex Bullock
Associate Professor
University of Oxford


Danette Daniels
Group Leader of Functional Proteomics
Promega

15.30 Virtual Networking & Poster Session

Exploring Autophagy, Screening-Based & Antibody Fragment Approaches to Induce Protein Degradation

Simon Bailey
Executive Vice President & Head of Discovery
Plexium

16.30 Discovery of New Molecular Glues in Immune-Oncology & CNS Diseases

- Pros and cons of 'molecular glues' vs PROTACS
- Discovery of new molecular glues using novel ultra-high throughput screening and chemistry platforms
- Application to drug discovery projects in I/O and CNS diseases

Terry Rabbitts
Professor of Molecular Immunology
The Institute of Cancer Research

16.50 Selective Protein Degradation in Cancer using Engineered Intracellular Antibodies or DARPIns

- Intracellular antibodies and DARPins are biologics that can be fused with E3 ligases by protein engineering
- Addition of these E3 ligase warheads elicits protein degradation when the biologics engage with their target proteins
- KRAS-selective biologics with fused to E3 ligases cause cancers with KRAS mutation to undergo apoptosis
- This is a general strategy for biologic-induced target protein degradation in cells

17.10 Discussion/Q&A


Simon Bailey
Executive Vice President & Head of Discovery
Plexium


Terry Rabbitts
Professor of Molecular Immunology
The Institute of Cancer Research

17.30 Chair's Closing Remarks & End of Day One

CONFERENCE DAY TWO
THURSDAY 18 MARCH

ALL TIMES SHOWN IN GMT

8.30 Morning Coffee & Virtual Networking

8.55 Chair's Opening Remarks

Advancing the Horizon & Impact of PROTAC-Based Targeted Degradation

9.00 Selecting Targets to Harness the Therapeutic Opportunities Afforded by PROTAC-mediated Protein Degradation

John Harling
Senior Scientific Director of Medicinal Chemistry
GSK

- With a significant proportion of the intracellular proteome likely being amenable to PROTAC-mediated degradation, considerable focus needs to be placed on identifying the best therapeutic opportunities for this technology
- This presentation will share some experiences at GSK assessing different targets and the consideration of whether a PROTAC approach represented the modality of choice
- Data will be presented highlighting how factors such as protein synthesis rates, the relationship between the extent of degradation and functional response as well as additional pharmacology that cannot be accessed via an inhibitor can impact this assessment

9.20 New Approaches to Degradation – Beyond the Usual Suspects

Ian Churcher
Chief Scientific Officer
Amphista Therapeutics

- Amphista Therapeutics uses a completely novel range of mechanisms to degrade a wide range of disease-relevant proteins
- Mechanisms go beyond the usual E3 ligases utilized by most in the field and instead use other UPS proteins which offer new opportunities to expand the scope and utility of TPD strategies
- We will discuss how novel mechanisms have the potential to overcome current limitations with TPD strategies

9.40 PROTAC-Mediated Degradation Reveals a Non-Catalytic Function of AURORA-A Kinase

Elmar Wolf
Professor
University of Würzburg

- Aurora-A kinase interacts with the MYC oncoprotein and is an established cancer target
- Kinase inhibitors have not been clinically successful, maybe because Aurora-A has non-catalytic functions
- We developed PROTACs which rapidly and specifically degrade Aurora-A in Cancer cells and present a novel pharmaceutical anti-cancer strategy

10.00 Building a PROTACs Toolbox for Contract Research

Tom Coulter
Director of Integrated Drug Discovery
Selvita

- Meeting our clients' needs on PROTAC projects
- Developing a proprietary approach to PROTAC discovery
- Creating valuable PROTAC assets

10.10 Discussion/Q&A

John Harling
Senior Scientific Director of Medicinal Chemistry
GSK

Ian Churcher
Chief Scientific Officer
Amphista Therapeutics

Elmar Wolf
Professor
University of Würzburg

Tom Coulter
Director of Integrated Drug Discovery
Selvita

10.40 Virtual Speed Networking

Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange digital business cards. Network and form lasting connections through this exclusive virtual speed networking!

Delving into Target Intrinsic Approaches & Degrader Design to Characterise Selective Protein Degradation

Laura Luh
Research Scientist
Bayer

11.30 Teaching an Old Dog New Tricks – Traditional Small Molecule Drug Discovery & Targeted Protein Degradation

- Setting up a screening cascade in an industrial environment
- Selected highlights from in-house projects
- Turning a traditional inhibitor into a degrader to introduce new biology

Alexander Scheer
Chief Scientific Officer
Aelin Therapeutics

11.50 Enhancing Applicability, Specificity & Effectivity: Leveraging the Potential of a Protein Aggregation Based Platform to Transform Drug Discovery

- Aelin's protein-aggregation based platform allows the targeting of previously undruggable target, since no requirement such as a specific binding- or active sites are anymore necessary to start drug discovery
- Through harnessing this new technology, we can overcome challenges surrounding discovery of new molecules for exciting but still "undruggable" oncology targets
- Outline of the technology and potential of the protein aggregation platform
- Aelin's platform as an alternative in the space of PROTACs

Agustina Rodriguez-Granillo
Principal Scientist II
Schrodinger

12.10 Computational Workflows for Bifunctional Degrader Design

- Presenting three computational workflows to address different design challenges of bifunctional degraders
- The workflows include the conformational sampling of the isolated bifunctional degrader, the determination of the degrader exit vector and the prediction of the target-degrader-ligase ternary complexes
- Preliminary method validation using available public crystal structures and highlights of their limitations

12.30 Discussion/Q&A

Laura Luh
Research Scientist
Bayer

Alexander Scheer
Chief Scientific Officer
Aelin Therapeutics

Agustina Rodriguez-Granillo
Principal Scientist II
Schrodinger

12.50 Lunch Break

Harnessing Alternative Next-Generation Platforms for Inducing Protein Degradation

Senior Representative
Refeyn

13.50 Session Title TBC

- The pioneer in mass photometry, Refeyn produces a disruptive new generation of analytical instruments that measure the mass of individual molecules directly in solution
- Mass photometry transforms our ability to characterise the composition, structure and dynamics of biomolecules, revealing the true behaviour of molecules in their native environment
- Refeyn instruments can show sample purity and homogeneity, analyse biomolecular complex assembly or disassembly, quantify strength and kinetics of complex molecular interactions and more

Paul Thompson
Chief Scientific Officer
Mission Therapeutics

14.00 Deubiquitylating (DUB) Enzyme Targeting for Treatment of Human Disease

- DUBs antagonise action of ubiquitin ligases – inhibiting the inhibitor
- DUB specificity/localization informs target/indication selection – USP30 as an example
- DUB/substrate/ligase partnership data mining for new opportunities
- DUB inhibition opportunities exist in neurodegenerative disease

Benedict Cross
Chief Technology Officer
PhoreMost

14.20 Next-Generation PROTAC Discovery with a Systematic Screening Engine

- Small molecule PROTAC development is hampered by a low complexity matrix of E3 recruitment modules, and hindered by a high degree of substrate specificity
- PhoreMost have developed SITESEEKER, an ultra-high throughput pooled phenotypic screening platform, exploiting high-diversity programmable drug mimetics
- Systematic application of the SITESEEKER tools to PROTAC discovery has yielded a substantial cache of novel E3 ligase ligands and peptide-based PROTACs which have been deployed to degrade key therapeutic targets

Gustavo Gutierrez
Principal Scientist
Galápagos NV

14.40 Involvement of the Deubiquitinase USP13 in Cancer

- Introduction to DUBs and to USP13 roles in cancer pathways
- Characterisation of two novel substrates of USP13 linked to cancer
- Discussion on inhibition of USP13 by small molecules

15.00 Discussion/Q&A

Senior Representative
Refeyn

Paul Thompson
Chief Scientific Officer
Mission Therapeutics

Benedict Cross
Chief Technology Officer
PhoreMost

Gustavo Gutierrez
Principal Scientist
Galápagos NV

15.30 Chair's Closing Remarks & End of TPD Europe Summit

"Targeted protein degradation is an emerging and highly promising new concept for drug discovery. The meeting will be an excellent platform to share successes and challenges as well as discussing future directions"

Guido Koch, Chief Executive Officer, **Amphilix AG**

PARTNER WITH US

100+ ATTENDEES

7+ HOURS OF DEDICTATED VIRTUAL NETWORKING

3 PRE-CONFERENCE WORKSHOPS

24 REAL WORLD CASE STUDIES

Benefits of Sponsoring a Digital Meeting

Build new relationships through targeted direct messaging & contact sharing capabilities

Showcase your expertise to senior decision makers through scheduled video meetings

Generate new & valuable leads through facilitated virtual speed networking sessions

Elevate your brand & cement your reputation through virtual exhibition booths

Differentiate your company from competitors by engaging in the new digital reality

Expertise Partner

We share your passion for science. Promega is committed to excellence in technologies to assess key processes in PROTAC- and molecular glue-induced protein degradation. From assessing protein degradation in real time, to ternary complex formation and more. Our CRIPSR content covers hundreds of pre-built targets. Assay live cells in kinetic mode to determine target protein degradation rates, DC50 potency values, and recovery profiles. Let's collaborate.
www.promega.com

Expertise Partner

HitGen, Inc. is a biotech company focused on DNA Encoded Library development and applications. HitGen's DELs currently contain more than 400 billion novel, diverse and drug-like small molecules, which are synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results on challenging targets such as PPI with high affinity. HitGen has also developed unique DELs and methods for identification of small molecules that can be used for targeted protein degradation.
www.hitgen.com/enxiandao/

Innovation Partner

Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions that accelerate and increase the efficiency of drug discovery and materials design. Founded in 1990, Schrödinger has nearly 400 employees and operations across the world. For more information, please visit:
www.schrodinger.com

Innovation Partner

Selvita is an integrated service company providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development. The company was established in 2007 and currently employs 450 professionals. Specialising in delivering integrated solutions Selvita has a proven track record of not just providing scientific excellence, but on building long-term partnerships with our clients and playing an active, consultative role in the project execution.
www.selvita.com

Innovation Partner

The pioneer in mass photometry, Refeyn produces a disruptive new generation of analytical instruments that measure the mass of individual molecules directly in solution. Mass photometry transforms our ability to characterise the composition, structure and dynamics of biomolecules, revealing the true behaviour of molecules in their native environment. Refeyn instruments can show sample purity and homogeneity, analyse biomolecular complex assembly or disassembly, quantify strength and kinetics of complex molecular interactions and more.
www.refeyn.com

Exhibition Partner

We are a CRO specialising in the analysis of proteins and their associated PTM's via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay. With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
www.proteomics.com

Exhibition Partner

Delve deeper into examining key targets involved in drug discovery, oncology, gene therapy and neurodegenerative disorders. Identify the critical molecules that influence targeted-protein degradation pathways with characterization tools from NanoTemper Technologies. We're committed to enabling researchers to easily, efficiently, and precisely characterize proteins. With systems, software and consumables for evaluating and screening binding affinities, protein stability and protein quality, scientists in academia, biotech and pharmaceuticals will experience improved workflows and quality results.
www.nanotempertech.com

> "At a personal level, the TPD Europe Summit is a unique networking opportunity, to identify the current leaders and main actors in the field in Europe (at both academic and industrial levels), to be able to interact with them and exchange ideas, and eventually also to start synergistic collaborations"
>
> **ustavo Gutierrez**, Principal Scientist, **Galápagos NV**

Who Will You Meet?

ATTENDEE SENIORITY



INDUSTRY BREAKDOWN



*Based on the 2nd TPD Summit attendees

GET INVOLVED

Jacob Roberts-Kendall
Partnerships Director
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.tpd-europe.com/register

Tel: +44 (0)20 3141 8700

Email: register@hansonwade.com

1. Discover the next generation of TPD approaches beyond the ubiquitin-proteasome system and oncology
2. Uncover the latest strategies to optimise to advance PROTAC-based therapeutics towards the clinic
3. Virtually network with the leading experts in the field to redefine your TPD pipelines

Team Discounts

- **10% discount – 3 delegates**
- **15% discount – 4 delegates**
- **20% discount – 5+ delegates**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

SECURE YOUR PLACE

Please select appropriate price when booking. Bookings are subject to approval.

Industry Pricing	Register & Pay by Friday 20 November	Standard Pricing
Conference + 3 Workshops	£2,216 **(Save £180)**	£2,396
Conference + 2 Workshops	£1,967 **(Save £180)**	£2,147
Conference + Workshop	£1,718 **(Save £180)**	£1,898
Conference Only	£1,469 **(Save £180)**	£1,649

Academic Pricing	Register & Pay by Friday 20 November	Standard Pricing
Conference + 3 Workshops	£1,796 **(Save £200)**	£1,996
Conference + 2 Workshops	£1,597 **(Save £200)**	£1,797
Conference + Workshop	£1,398 **(Save £200)**	£1,598
Conference Only	£1,199 **(Save £200)**	£1,399

Please note: If you are purchasing a digital ticket option and you are a UK or EU-based company, you may be subject to 20% VAT in addition to the price advertised. If you qualify for a reverse charge you will have the option to provide your VAT number and the charge will be automatically deducted at checkout. Visit the website for more details. Please select appropriate price when booking. Bookings are subject to approval.